Lilly drug fails in breast cancer trial, shares fall

By Esha Dey and Bill Berkrot (Reuters) - Eli Lilly and Co said it will not seek a breast cancer approval for one of its most closely watched experimental drugs after it failed to significantly delay disease progression and showed no survival benefit in a late-stage trial. The drug, ramucirumab, has been successful in gastric cancer trials and is also being tested for colon, liver and lung cancers, with key late stage data on those three expected next year. But Lilly shares fell more than 3 percent after it released the disappointing breast cancer results. ...



via Health News Headlines - Yahoo! News http://news.yahoo.com/lilly-drug-fails-breast-cancer-succeeds-gastric-cancer-131148496--finance.html